NanoViricides (NNVC) Stock Price, News & Analysis

Company Overview

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Key Stats

• Today's Range: $1.56 to $1.60
• 50-Day Range: $1.23 to $1.75
• 52-Week Range: $0.94 to $2.34
• Volume: 61,387 shs
• Average Volume: 248,685 shs
• Market Capitalization: $25.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NanoViricides Stock Analysis - MarketRank™

NanoViricides scored higher than 6% of companies evaluated by MarketBeat, and ranked 915th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NanoViricides.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NanoViricides is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NanoViricides is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NanoViricides has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.66% of the outstanding shares of NanoViricides have been sold short.

Short Interest Ratio / Days to Cover

NanoViricides has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoViricides has recently decreased by 56.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NanoViricides does not currently pay a dividend.

Dividend Growth

NanoViricides does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.66% of the outstanding shares of NanoViricides have been sold short.

Short Interest Ratio / Days to Cover

NanoViricides has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoViricides has recently decreased by 56.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

8 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NanoViricides insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of NanoViricides is held by insiders.

Percentage Held by Institutions

Only 10.30% of the stock of NanoViricides is held by institutions.

NNVC Stock Analysis - Frequently Asked Questions

How have NNVC shares performed this year?

NanoViricides' stock was trading at $1.43 at the beginning of 2025. Since then, NNVC stock has increased by 10.5% and is now trading at $1.58.

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSE:NNVC) posted its earnings results on Friday, September, 27th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01.

When did NanoViricides' stock split?

NanoViricides shares reverse split on the morning of Tuesday, September 24th 2019.The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of NanoViricides?

Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), NVIDIA (NVDA), Micron Technology (MU), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 9/27/2024
• Today: 8/10/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NNVC
• CIK: 1379006
• Web: www.nanoviricides.com
• Phone: (203) 937-6137
• Fax: 203-859-5095
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.90%
• Return on Assets: -78.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 16,072,000
• Free Float: 14,922,000
• Market Cap: $25.39 million
• Optionable: Optionable
• Beta: 0.96